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a  b  s  t  r  a  c  t
Recombinant  human  erythropoietin  (rhEPO)  is an  important  CHO  cell-derived  glycoprotein  and  the
degree  of sialylation  of  this  hormone  is  crucial  for its in  vivo  bioactivity.  In  order  to  improve  the  puriﬁca-
tion  process  serotonin  as a potential  afﬁnity  ligand  was  tested  for  preparative  chromatographic  separation
of rhEPO  glycoforms  into  fractions  of different  degrees  of  sialylation.  Therefore,  two  chromatographic
matrices  were prepared  by  immobilizing  serotonin  on  CNBr-  and NHS-SepharoseTM. First  it was  shown
both  matrices  bind  rhEPO  only  in  its sialylated  form.  Results  indicate  that  binding  is pH  independent
between  pH  3.5 to 8  suggesting  it is  not  only  based  on electrostatic  interactions.  Second,  after  optimal
binding  conditions  were  identiﬁed,  semi-puriﬁed  rhEPO  was  loaded  onto  both  matrices  and  eluted  using
a stepwise  elution  gradient  of  sodium  chloride.  For  comparison  same  afﬁnity  puriﬁcation  experiments
were  performed  using  wheat  germ  agglutinin-coupled  agarose,  a lectin  known  for its  afﬁnity  towards
sialylated  glycoproteins.  To  monitor  changes  in  N-glycan  ﬁngerprint,  eluate  fractions  were  analyzed  by
multiplexed  capillary  gel  electrophoresis  coupled  to laser-induced  ﬂuorescence  (xCGE-LIF).  For  the  sero-
tonin  matrices  an  increasing  degree  of  sialylation  was  observed  from  the  ﬁrst  to  the  third  elution  fraction
while  purity  of  rhEPO  could  be increased  at the  same  time.  The  late  elution  fractions  of  serotonin-coupled
TMCNBr-  and NHS-Sepharose also  showed  an  overall  sialylation  degree  exceeding  that  of  the starting
material.  In contrast,  for rhEPO  bound  to wheat  germ  agglutinin-coupled  agarose,  no  distinct  change  in
the  degree  of  sialylation  could  be observed  after  elution.  Overall,  these  encouraging  results  highlight  the
potential  of  serotonin  as a chromatographic  ligand  for the  improvement  of pharmaceutical  puriﬁcation
processes  of rhEPO.
© 2016  Elsevier  B.V.  All  rights  reserved.Abbreviations: A, 280280UV adsorption units at 280 nm;  A280,max, UV maxi-
um; AEPO, asialo erythropoietin; AU, adsorption units; be, Blue SepharoseTM
luate (intermediate puriﬁcation step); CBQCA, 3-(4-carboxybenzoyl quinoline-
carboxaldehyde); xCGE-LIF, multiplexed capillary gel electrophoresis coupled to
aser  induced ﬂuorescence detection; CHO, Chinese hamster ovary; DBC, dynamic
inding capacity; ds, desialylated; E, elution; EB, elution buffer; EPO, erythropoietin;
b,  ﬁnal bulk; FT, ﬂow through; GlcNAc, N-acetylglucosamine; MTU, migration time
nits; RB, running buffer; rh, recombinant human; RT, room temperature; S, strip-
ing; SD, standard deviation; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
lectrophoresis; VR, retention volume; WGA, wheat germ agglutinin.
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The recombinant human glycoprotein hormone erythropoietin
(rhEPO) has one of the highest market shares among biophar-
maceuticals worldwide. With increasing demands and companies
facing competition by biosimilar manufacturers, process optimiza-
tion plays a crucial role. In vivo rhEPO stimulates the differentiation
of erythroid progenitor cells into mature erythrocytes, thus playing
an important role in red blood cell production [1–4]. Patients suffer-
ing from anemia, i.e. due to renal failure, AIDS or cancer treatment,
depend on external supply of rhEPO [5]. The 34 kDa glycoprotein
holds three N-glycosylation sites (Asn-24, Asn-38, and Asn-83), and
one O-glycosylation site (Ser-126) [6,7]. As for other glycoproteins,
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hEPO production is typically performed in Chinese hamster ovary
CHO) cells [8,9].
For rhEPO, as for many other glycoproteins, the degree of sialyla-
ion is essential for its in vivo bioactivity. While desialylated asialo
PO (AEPO) has a higher in vitro bioactivity, the in vivo half-life
f AEPO is approximately twenty times lower because the sialic
cid protects the hormone from being cleared from the blood by
alactose binding proteins of hepatic cells [10,11]. In vivo bioac-
ivity of rhEPO is also inﬂuenced by the branching of the glycan
tructures and the overall number sialic acids. For instance, it was
hown that the tetrasialylated tetra-antennary N-glycan content
s signiﬁcantly and positively correlated with in vivo bioactivity
12–15]. In recombinant protein production it is well known that
election of culture conditions, cell line, media, and feeding strategy
as an impact on the glycosylation of recombinant glycoproteins
n upstream processing [13,16–18]. For key properties of biophar-
aceuticals, i.e. bioactivity, a speciﬁc and consistent glycosylation
attern is required to guarantee product quality. However, batch-
o-batch variability in terms of glycoforms is a challenging concern
n biopharmaceutical production processes [19]. Therefore, it is
mportant to control the composition of glycoforms of the end
roduct during downstream processing of cell culture harvests.
Currently it is not possible to express rhEPO only in its natural
ighly sialylated form in cell culture. Hence, in order to preserve
 high bioactivity, low sialylated glycoforms have to be removed
uring the puriﬁcation process. Often, this is achieved in one of the
ast unit operations in the puriﬁcation train by ion exchange chro-
atography (IEC) [6,20–24]. However, this separation method is
ased on the overall accessible charge of the glycoproteins and not
articularly on the degree of sialylation depending on the num-
er of negatively charged terminal sialic acids on the glycans. In
ddition, the overall charge of glycoproteins is also inﬂuenced by
hosphorylation and sulfation, which may  differ from batch to
atch. As a result, separation of less sialylated but more strongly
hosphorylated or sulfated proteins may  occur [13,25–27]. An
ttractive alternative to IEC for separation of glycoforms would be
he use of suitable sialic acid-speciﬁc ligands. In the past, lectins,
atural proteins binding carbohydrates from plants or animals
28–30], have been used for glycoprotein puriﬁcation [31–33].
owever, lectins are frequently toxic and therefore do not com-
ly with safety regulations for human pharmaceutical production
rocesses [34–36]. In addition, similar to the use of antibodies, the
igh costs of lectins renders their use in large scale puriﬁcation
conomically unattractive. A promising option, however, seems
o be serotonin, a small and nontoxic molecule [37–39] whose
iochemical and pharmacokinetic properties are well character-
zed [39]. and which is commercially available at a relatively low
rice. Afﬁnity of serotonin towards sialylated glycoproteins was
rst reported by Ochoa and Bangham in 1976 [40]. Since then it
as used successfully in several laboratory scale processes (liq-
id chromatography and solid phase extraction) for the analysis
41,42] and puriﬁcation [43,44] of glycans, glycopeptides, and gly-
oproteins using serotonin-immobilized silica or Sepharose beads.
owever, while these studies showed the potential of serotonin
or isolating sialylated glycoproteins, it has not been used for the
reparative fractionation of glycoforms of a sialylated glycoprotein
o far.
Here, we describe the development of a preparative afﬁnity
hromatographic process for the puriﬁcation and fractionation of
hEPO glycoforms, based on the interaction of their sialylated gly-
omoieties with respective immobilized ligands. The evaluation of
his process involved the immobilization of serotonin onto differ-
nt chromatographic matrices to study its separation performance
n small scale afﬁnity chromatography. As a control matrix immo-
ilized wheat germ agglutinin (WGA), a lectin with known binding
roperties and afﬁnity towards sialyllactose [45,46], was used. For 1012-1013 (2016) 193–203
a better understanding of the fractionation efﬁciency of the pro-
cess with respect to the glycosylation pattern, glycoproﬁling was
performed. Based on multiplexed capillary gel electrophoresis cou-
pled to laser induced ﬂuorescence detection (xCGE-LIF), detailed
information about the glycosylation patterns of the distinct afﬁnity
chromatographic fractions could be gained [47–49].
2. Material and methods
2.1. Materials and reagents
Milli-Q advantage A10 system (Millipore, USA) to produce ultra-
pure water used for all experiments and solutions. Hydrochloric
acid (HCL, #1003171000, Merck KGaA, Darmstadt, Germany) and
sodium hydroxide (NaOH, #6771, Carl Roth GmbH & Co. KG,
Karlsruhe, Germany) for setting the pH of buffers. Serotonin
HCL (#B21263, Alfa Aesar GmbH & Co. KG, Karlsruhe, Germany).
Sodium borate (borax, #S9640-500G), ethanolamine (#E9508-
100ML), and sodium acetate (#71183), all from Sigma–Aldrich
(Steinheim, Germany). Sodium hydrogen carbonate (NaHCO3,
#6885.2), Tris (#5429.1), ethanol (#5054.1), acetic acid (#7332.1),
sodium chloride (NaCl, #P029.1), di-sodium hydrogen phosphate
(#P030.1), and sodium di-hydrogen phosphate monohydrate (##
K300.1), all from Carl Roth GmbH & Co., KG (Karlsruhe, Germany.
Sodium phosphate buffer was prepared by mixing Sodium di-
hydrogen phosphate solution with di-sodium hydrogen phosphate
solution). CNBr-activated SepharoseTM 4B (CNBr-SepharoseTM,
#17-0430-01) and NHS-activated SepharoseTM 4 Fast Flow (NHS-
SepharoseTM, #17-0906-01), both from GE Healthcare Bio-Science
AB (Uppsala, Sweden). Agarose wheat germ agglutinin (WGA-
agarose, #AL-1023, Vector Laboratories Ltd., Peterborough, United
Kingdom). Control agarose resin (#26150, Thermo Scientiﬁc, Rock-
ford, Illinois, USA). Eppendorf Protein LoBind Tubes (Eppendorf
AG, Hamburg, Germany) and low binding tips from Sorensen Bio
Science, Inc. (Salt Lake City, Utha, USA) to reduce losses due to
unspeciﬁc binding during assay quantiﬁcation. Thermomixer com-
fort (Eppendorf AG, Hamburg, Germany) for incubation, agitation
and temperature control. Tecan inﬁnite M200 Pro plate reader
(Tecan Group Ltd., Männedorf, Switzerland) to read out microtiter
plates.
All materials containing rhEPO were obtained from Mer-
ckle Biotec GmbH (TEVA, Ulm, Germany). This included partially
puriﬁed rhEPO (rhEPObe, obtained after blue SepharoseTM chro-
matography), the puriﬁed ﬁnal bulk (rhEPOfb, obtained at the end
of the process train after IEC), and rhAEPO (enzymatically desialy-
lated rhEPOfb) all expressed in CHO cells.
2.2. Preparation of serotonin matrices
Serotonin matrices were prepared by coupling serotonin to
two different matrices, CNBr-Sepharose and NHS-SepharoseTM.
While the active group of the ﬁrst material is directly linked to
the SepharoseTM the NHS possesses a 10-atom spacer between
the matrix and the active group. Serotonin was immobi-
lized via its amine on CNBr-SepharoseTM (further referred to
as serotonin-CNBr) by the cyanogen bromide method, follow-
ing the manufacturer’s instructions Brieﬂy, 2 g of lyophilized
CNBr-SepharoseTM were suspended in 1 mM HCl, pH 3.0 and subse-
quently washed with 1 mM HCl for 15 min  on a sintered glass ﬁlter
with a ﬁber glass ﬁlter on top. 40 mg serotonin-HCl were solved
in 10 ml  coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3) and
added to the activated CNBr-SepharoseTM in 15 ml  reaction tubes.
The tubes were protected from light and then incubated for 2 h at
room temperature (RT) by rotating the mixture with a Multi Bio
RS-24 (Kisker Biotech GmbH & Co., KG, Steinfurt, Germany). After
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ncubation, excess ligand was washed away with 35 ml  coupling
uffer. Following, the suspension was incubated with 10 ml  of 1 M
thanolamine, pH 8.0 for 1 h at RT in order to block any remaining
ctive groups. After blocking, the material was washed with three
ycles of alternating pH (0.1 M sodium acetate, 0.5 M NaCl, pH 4.0
nd 0.1 M Tris–HCl, pH 8.0). The ﬁnal product was then washed
ith 50 ml  ultra-pure water followed by 50 ml of 20% (v/v) ethanol
nd stored in light protected reaction tubes at 4 ◦C.
Serotonin immobilization on NHS-SepharoseTM (fur-
her referred to as serotonin-NHS) was  done via the
-hydroxysuccinimide method according to the manufacturer’s
nstructions. The procedure differs from the procedure of CNBr-
epharoseTM coupling as follows. All solutions were cooled down
o 4 ◦C. 5 ml  drained NHS matrix as well as 296 mg  serotonin,
olved in 2.5 ml  coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH
.3) have been used. During the coupling reaction pH had to be
djusted to pH 8.0. For blocking 0.5 M ethanolamine with 0.5 M
aCl, pH 8.3 was added.
Preparations of the negative control matrices ethanolamine-
NBr and ethanolamine-NHS were done analogous skipping the
mmobilization step of serotonin. After washing, all materials were
ept light protected at 4 ◦C until use. Immobilization was  evaluated
y elementary analysis performed by Dr. Sabine Busse and Sabine
reiß from the Institute of Chemistry of the Otto-von-Guericke Uni-
ersity (Magdeburg, Germany).
.3. Dialysis
For dialysis cellulose ester Spectra/Por Biotech Dialysis Tubes
ith a molecular weight cut off of 3.5–5 kDa (Spectrum Laborato-
ies Inc., Rancho Dominguez, CA, USA) were used. Dialysis ran over
ight with a buffer exchange after 4 h resulting in a sample to buffer
atio of at least 1:1,000.
.4. Chromatography
All experiments were performed with an ÄKTA Explorer or
KTA Basic system and TricornTM 5/20High Performance columns
ith an inner diameter of 5 mm (all GE Healthcare Bio-Science,
ppsala, Sweden) and packed with the respective afﬁnity matrix.
olumns were kept at 4 ◦C during experiments using a Thermo
cientiﬁc water bath V15 (Thermo scientiﬁc, Germany). Unless
therwise stated the following steps and ﬂow rates were used
n chromatography: Equilibration with running buffer (composi-
ion of buffers below) (0.5 ml/min); sample injection (0.25 ml/min);
ashing with running buffer (0.25 ml/min); elution with elution
uffer (0.5 ml/min); stripping with stripping buffer (1 ml/min); re-
quilibration with running buffer (1 ml/min). 500 mM NaCl solved
n running buffer was used as stripping buffer for all experiments.
V adsorption units at 280 nm (A280), conductivity, and pH values
ere recorded online as required. Peaks of the chromatogram were
haracterized by maximum A280 (A280,max) and retention volume
VR). If necessary, fractions were collected for further analysis.
.4.1. Optimization of buffer conditions and test of binding
peciﬁcity
All columns were packed with approximately 300 l of the
espective matrix. Chromatograms were evaluated using blank
uns (without rhEPOfb) to discriminate between effects of buffer
omposition and protein elution on the UV signal. In all experi-
ents the columns were loaded with 100 g of sample (rhEPOfb,
hEPObe or rhAEPO) 1:4 diluted in running buffer. The binding and
lution behavior was evaluated on the basis of the UV-signal at
80 nm.
To investigate the inﬂuence of the pH value, a serotonin-CNBr
olumn was used with 50 mM sodium phosphate, pH 6 as running 1012-1013 (2016) 193–203 195
buffer. After loading rhEPOfb and washing of the column, elution
was performed with a 18 ml  linear gradient from 0 to 100% of
50 mM sodium acetate, pH 3.5 (pH was  adjusted with acetic acid)
or 50 mM sodium phosphate, pH 8.0; the pH value was monitored
online.
To test the effect of ionic strength on elution, a serotonin-CNBr
column was used with 20 mM sodium phosphate, pH 6 as running
buffer. After loading rhEPOfb and washing, the elution was done
with a 9 ml  linear gradient from 0 to 100% of 20 mM sodium acetate,
pH 6.0 with 500 mM NaCl.
In addition, the binding speciﬁcity of the serotonin matrices to
sialylated rhEPO was tested. Therefore, rhEPOfb or rhAEPO were
diluted in running buffer (20 mM sodium phosphate, pH 6.0) and
applied to serotonin-CNBr and ethanolamine-CNBr as well as to
the negative controls serotonin-NHS and ethanolamine-NHS. After
loading, the columns were washed and the bound material eluted
using 500 mM NaCl in running buffer. To examine whether the
running buffer has an impact on binding speciﬁcity, this test was
repeated with three other running buffers (sodium acetate, ammo-
nium acetate, and MES).
The elution gradients where optimized for serotonin-CNBr,
serotonin-NHS and WGA-agarose. Step gradients (two different
NaCl gradients of 10 steps; 4.5 ml  per step) were applied to test the
sodium chloride concentration, at which rhEPO can be eluted from
the matrices. In all experiments rhEPObe was  loaded. The ﬁrst run
was performed using a gradient of 0 mM–100 mM NaCl in running
buffer (20 mM sodium phosphate, pH 6.0) and the second run using
a gradient of 0 mM–300 mM NaCl in running buffer (for WGA  0 mM
to 500 mM).  NaCl concentrations at which a distinct UV-peak was
visible were selected as elution steps for the fractionation experi-
ments. The elution strategy for each material was  tested before the
fractionation experiments and adjusted if necessary.
2.4.2. Dynamic binding capacity estimation
Columns were packed with approximately 100 l of respec-
tive matrix. rhEPOfb was dialyzed against running buffer (20 mM
sodium phosphate, pH 6.0). The dialyzed sample was loaded onto
the column until the UV signal exceeded 10% of UV maximum
indicating breakthrough. Dynamic binding capacity (DBC) was  cal-
culated from the load concentration and the total load volume at
10% breakthrough.
2.4.3. Fractionation of partially puriﬁed rhEPObe
rhEPObe, dialyzed against running buffer (20 mM sodium phos-
phate, pH 6.0), was used as load sample. Columns were packed
with approximately 500 l of respective matrix and samples were
loaded with about 20% of the respective DBC. After loading and
washing the bound material was  eluted with a 3-step gradient that
was adapted to the elution behavior of the respective column (see
2.4.1.). 0.3 M NaCl in running buffer was used as elution buffer and
fractions (1 ml/fraction) of the whole run were collected. Fractions
of a single peak were pooled prior analysis. For separations using
WGA-agarose, the chromatographic method was  identical except
that a 1 ml  Tricorn column was  applied, and 0.5 M and 1 M NaCl was
used as buffer for elution and stripping, respectively.
2.5. Analysis
2.5.1. rhEPO ELISA
rhEPO concentration was determined with an rhEPO-speciﬁc
enzyme linked immune sorbent assay (ELISA) kit (Merckle Biotec
GmbH, Ulm, Germany). Analysis was done according to the manu-
facturer’s instructions. Brieﬂy, samples were diluted at least 1:100
in the assay buffer of the kit. 100 ml  of each sample and standard
(1 ng/ml to 20 ng/ml rhEPOfb), all in duplicates, were added to a
pre-coated 96-well plate and incubated for 60 min  in the thermo
1 togr. B
m
4
t
1
I
a
T
O
m
o
r
2
w
[
(
w
d
a
m
2
a
b
g
t
a
s
b
d
T
B
c
F
a
t
(
t
T
S
t
2
L
w
(
a
t
B
r
f
S
ﬂ
(
l
m
x
e
w
s
[
p
n96 M. Meininger et al. / J. Chroma
ixer at 600 rpm and RT. Subsequently the plate was washed with
 cycles of assay buffer. 100 l of enzyme conjugate was added
o each well followed by incubation and washing as before. Then
00 l of substrate/chromogen solution was added to each well.
ncubation was stopped after a light blue color had developed by
dding 100 l of stop solution. The plate was read out at 450 nm.
he assay was validated in a range of 2 ng/ml to 20 ng/ml rhEP-
fb and samples were measured in duplicates (relative SD of the
ethod 1.98%). (Note: this assay does not enable differentiation
f rhEPO obtained from individual puriﬁcation steps, i.e. rhEPObe,
hEPOfb, and rhAEPO).
.5.2. Bradford assay
Samples with an expected protein concentration above 5 g/ml
ere analyzed using the Bradford assay as published previously
50]. As protein assay dye reagent Coomassi Brilliant Blue G-250
Bio-Rad Laboratories, München, Germany) was used. The assay
as calibrated according to an internal standard operating proce-
ure using rhEPOfb in a range of 5–40 g/ml. If necessary, standards
nd samples were diluted in phosphate buffered saline (PBS). All
easurements were done in triplicates.
.5.3. CBQCA (3-(4-carboxybenzoyl quinoline-2carboxaldehyde)
ssay
If protein concentration was below 5 g/ml, it was measured
y the CBQCA Protein Quantitation Kit (Invitrogen, Eugene, Ore-
on, USA). Detection is based on the ATTO-TAG CBQCA reagent
hat forms highly ﬂuorescent derivatives by reacting with primary
mines in the presence of cyanide (You et al., 1997). Samples and
tandards (rhEPOfb) were ﬁrst diluted 1:2 with 100 mM borax
uffer, pH 9.3. Further dilutions were done with working buffer (1:2
ilution of 100 mM borax buffer with respective sample buffer).
he rest of the procedure followed the manufacturer’s instructions.
rieﬂy, 135 l of each sample were transferred to a black ﬂuores-
ence low binding 96 well microtiter plate (Greiner Bio-One GmbH,
rickenhausen, Germany). 5 l of 20 mM potassium cyanate were
dded followed by 10 l of 5 mM CBQCA reagent after quick agi-
ation. The plate was protected from light and incubated for 1 h
1000 rpm, RT). The ﬂuorescence signal was measured at an excita-
ion and emission wavelength of 465 nm and 550 nm,  respectively.
he assay was validated in a range of 0.2 g/ml–2.0 g/ml (relative
D of the method 4.3%). Samples were measured in quintuplicates
o identify outliers which occurred frequently.
.5.4. Glycan analysis
N-glycosylation of rhEPO samples was analyzed by xCGE-
IF according to [47–49]. Brieﬂy, samples were ﬁrst enriched
ith 3 kDa MWCO  Amicon Ultra-0.5 centrifugal ﬁlter units
#UFC500324, Merck-Millipore, Darmstadt, Germany) and sep-
rated with sodium dodecyl sulfate polyacrylamide gel elec-
rophoresis (SDS-PAGE). Bands were excised from Coomassie
lue-stained SDS-PAGE gels between 28 kDa and 40 kDa, where
hEPO should accumulate. N-glycans were enzymatically released
rom rhEPO protein backbone by peptide-N-glycosidase F (#P7367,
igma-Aldrich, Steinheim, Germany) treatment and subsequently
uorescently labeled with 8-aminopyrene-1,3,6-trisulfonic acid
APTS, #09341, Sigma–Aldrich, Steinheim, Germany). The APTS
abeled N-glycans were puriﬁed by hydrophilic interaction chro-
atography (HILIC) in solid phase extraction mode, followed by
CGE-LIF measurement [51]. For analyzing xCGE-LIF generated
lectropherograms, glyXtoolTM (glyXera, Magdeburg, Germany)
as used, including migration time normalization to an internaltandard from glyXera, generating so called N-glycan ﬁngerprints
52]. As master proﬁle standard the N-glycan ﬁngerprint of CHO cell
roduced rhEPOfb was used (Fig. 1). Due to the highly reproducible
ormalized migration times a peak assignment with N-glycan 1012-1013 (2016) 193–203
structures to an in-house database could be performed. Further-
more, for quantitative comparison, the relative peak height (RPH:
ratio of peak height to the total height of all peaks) of each peak
within the N-glycan ﬁngerprint was calculated representing the
relative concentration of at least one respective N-glycan structure
beyond the peaks.
3. Results and discussion
3.1. Ligand immobilization
Serotonin was  coupled to CNBr-SepharoseTM and NHS-
SepharoseTM. To evaluate the immobilization efﬁciency of
serotonin to the respective matrix, an elementary analysis was
performed. The change in nitrogen content was used to evaluate
serotonin coupling. For serotonin-CNBr nitrogen content increased
by 307 mol/g dried material. Since the number of nitrogen atoms
increases by 2 per coupled serotonin molecule, this corresponds
to 153.5 mol  coupled serotonin per gram of dried material. For
serotonin-NHS nitrogen content increased by 435 mol/g of dried
material. Since the number of nitrogen atoms increases by 1 per
coupled serotonin molecule, this corresponds to 435 mol  coupled
serotonin per gram of dried material. In case of NHS-SepharoseTM
the maximum number of coupling sites is about 80 mol/g dried
material which is more than ﬁve times lower than the calculated
amount of coupled serotonin. In case of CNBr-SepharoseTM no num-
ber of coupling sites is given by the manufacturer. Assuming the
number is similar to NHS-SepharoseTM the calculated amount of
coupled serotonin exceeds this number almost two times. It looks
like in both cases nitrogen has not only been introduced by sero-
tonin but also by unexpected side reactions. Clearly, elementary
analysis is a method for proving qualitative success of ligand cou-
pling rather than giving quantitative numbers. But from the high
increase in nitrogen content for both materials full saturation is
assumed.
3.2. Scouting experiments for determination of optimal binding
conditions
Different binding and elution conditions were tested as well as
negative controls to demonstrate principal functionality.
3.2.1. Buffer conditions
To investigate the effect of increasing and decreasing pH on elu-
tion rhEPOfb was loaded onto serotonin-CNBr matrix using a linear
elution gradient (Fig. 2). Since only pure rhEPOfb was loaded the
obtained UV-signal reﬂects changes in the rhEPOfb concentration.
For both experiments (Fig. 2A and B) very low amounts of rhEP-
Ofb were eluted shown by low UV signals during the elution step
which are slightly above the signals of the blank runs (Fig. 2C and D).
The high peak (A280,max = 78.4 mAU, VR = 31.1 ml)  during the strip-
ping step after pH decrease from pH 6.0 to 3.5 (Fig. 2A) conﬁrmed
that most of the rhEPOfb was still bound. Even when the isoelec-
tric point of rhEPOfb, which ranges between pH 4.2 and 4.6 [8]
was exceeded, no elution occurred. When rising the pH from 6 to 8
(Fig. 2B) a smaller peak (A280,max = 40.3 mAU, VR = 31.2 ml)  during
the stripping step suggested that either part of the bound rhEPOfb
eluted before or that the binding strength was increased because
of the increased sialic acid charge so that the ionic strength of the
stripping buffer was not sufﬁcient for full elution. Since no signiﬁ-
cant elution was  observed while changing the pH the latter seems
more reasonable. This results support the ﬁndings of Sturgeon and
Sturgeon [43] who  reported that ion exchange effects are negligi-
ble for the binding of sialic acid to serotonin. On the other hand it
would be in contrast to the study of Ochoa and Bangham [40] who
proposed that the interaction is mainly electrostatic.
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Fig. 1. N-glycan ﬁngerprint of CHO cell-produced recombinant human erythropoietin ﬁnal bulk (rhEPOfb). Measured by multiplexed capillary gel electrophoresis coupled to
laser  induced ﬂuorescence detection. The black continuous line depicts the signal intensity in relative ﬂuorescence units (RFU) over normalized migration time units (MTU”).
Peaks  assigned to one or more N-glycan structure(s) (listed in Table 1) are indicated by peak numbers.
Fig. 2. Effect of pH value on elution. (A,B) recombinant human erythropoietin ﬁnal bulk (rhEPOfb) was  loaded (running buffer 50 mM sodium phosphate, pH 6.0) onto
serotonin-CNBr (300 l in a Tricorn 5/50 column). After sample injection a linear elution gradient from 0 to 100% of elution buffer (A,C) 50 mM sodium acetate, pH 3.5; (B,D)
50  mM sodium phosphate, pH 8.0) was applied. (C) and (D) are blank runs where running buffer was injected instead of rhEPOfb. UV-absorption at 280 nm (A280) which
r isplay
t cess st
d
t
s
w
5
t
beﬂects changes in the protein concentration (rhEPOfb or rhAEPO, respectively) is d
he  buffer as red discontinuous line ( ), and pH as green dotted line ( ). Pro
otted  line ( ).
Besides testing the inﬂuence of pH the effect of salt concen-
ration on elution was tested as well (data not shown). It could be
een that binding of rhEPOfb is very sensitive to NaCl concentration
hich should not exceed 20 mM in the running buffer. In particular,
00 mM NaCl (1 M in case of WGA) in the running buffer was found
o be sufﬁcient as stripping buffer. This is not surprising since it has
een frequently reported that interaction of carbohydrates withed as blue continuous line ( ), conductivity, which reﬂects the ionic strength in
eps: load/ﬂow through (FT), elution (E), and stripping (S) are separated by a black
other materials is comparatively low and afﬁnity constants can be
found in the mM range [53–57].
Sodium phosphate, sodium acetate and ammonium acetate
showed similar results while the use of MES  buffer caused a shift
in the UV-signal that could not be explained. 20 mM sodium phos-
phate (pH 6.0) was chosen as running buffer. Based on experimental
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Fig. 3. Test of basic functionality of serotonin-CNBr. Binding of recombinant human erythropoietin ﬁnal bulk (rhEPOfb) and asialo rhEPOfb (rhAEPO) to serotonin-CNBr
(A  and B) and ethanolamine-CNBr (C and D) (running buffer (RB) 20 mM sodium phosphate buffer, pH 6.0). Bound rhEPOfb or rhAEPO was eluted with 500 mM NaCl in
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etups reported elsewhere [58] these binding conditions were
ssumed to be suitable for WGA-agarose as well.
After the optimization of the elution conditions, sodium chlo-
ide concentrations were identiﬁed at which EPO fractions do elute
data not shown). For serotonin-CNBr and for serotonin-NHS three
lution fractions were obtained, for WGA-agarose only two. To test
he suitability of NaCl as elution buffer for WGA-agarose, a column
as loaded with pure rhEPOfb until saturation and eluted with 1 M
aCl in running buffer (as described in the method for dynamic
inding capacity testing). The amount of rhEPO in the elution frac-
ion was comparable to the calculated dynamic binding capacity
or WGA-agarose. Also, the addition of N-acetyl-d-glucosamine
GlcNAc) to the elution buffer was tested for WGA-agarose. How-
ver, its use was found not to be practical in this study. When using
lcNAc it did not result in a better fractionation compared to NaCl.
urthermore, the use of GlcNAc as a component of the elution buffer
hould be avoided due to possible interference of glycans in the sub-
equent glycan analysis. Overall, it can be assumed that NaCl can be
sed for elution at sufﬁcient concentrations and that highly sialy-
ated EPO will bind stronger to WGA  and therefore eluate at higher
onic strength of the elution buffer.
.2.2. Test of speciﬁc binding
In order to demonstrate the basic functionality of both serotonin
atrices several positive and negative controls were performed.
herefore, rhEPOfb and rhAEPO were loaded onto serotonin-CNBr,
erotonin-NHS, and the negative controls ethanolamine-CNBr and
thanolamine-NHS (Fig. 3 and Fig. 4). After loading rhEPOfb
nto the serotonin-CNBr column a small UV-peak (A280,max = 7.8
AU, VR = 1.7 ml)  appeared during ﬂow through and a large peak
A280,max = 32.3 mAU, VR = 12.2 ml)  during elution showing that
ost of the loaded rhEPOfb has bound to the serotonin-CNBr col-(rhEPOfb or rhAEPO, respectively) is displayed as blue continuous line ( ), and
). Process steps: load/ﬂow through (FT) and elution (E) are separated by a black
umn  (Fig. 3A). The ﬂow through peak indicates that low quantities
of rhEPOfb did not bind. This could not be veriﬁed by later experi-
ments where the ﬂow through fraction was analyzed by the rhEPO
ELISA where no rhEPO could be detected. Since loaded samples
were not dialyzed against running buffer but diluted 1:8 with run-
ning buffer the ﬂow through peak could also be due to changes
in sample buffer composition. Loading of rhAEPO resulted in a
larger peak (A280,max = 23.6 mAU, VR = 2.8 ml)  during ﬂow through
and a much smaller peak (A280,max = 4.5 mAU, VR = 20.1 ml)  dur-
ing elution (Fig. 3B). This strongly suggests that serotonin-CNBr
does not bind rhAEPO. Nevertheless, low amounts of the rhAEPO
sample might still be available for binding to serotonin-CNBr
because rhAEPO is not totally free of sialic acid after enzymatic
digestion (information by MERCKLE BIOTEC). The negative control,
using ethanolamine-CNBr did neither bind rhEPOfb nor rhAEPO
(Fig. 3C and D). Accordingly, rhEPOfb as well as rhAEPO was found
mainly in the ﬂow through as indicated by the large UV-peaks
(A280,max = 59.8 mAU, VR = 2.0 ml;  A280,max = 56.5 mAU, VR = 2.0 ml)
during loading. Overall, results clearly demonstrated that serotonin
is necessary for the binding of rhEPOfb and that rhAEPO or low
sialylated rhEPO is not binding to the ethanolamine-CNBr matrix
used.
Additional experiments were performed using serotonin-
and ethanolamine-NHS. When loading rhEPOfb it bound almost
completely to the matrix (Fig. 4A). In contrast, two UV-
peaks (A280,max = 56.7 mAU, VR = 11.5 ml;  A280,max = 38.8 mAU,
VR = 13.9 ml)  were visible during elution. Interestingly, analysis by
Bradford assay and rhEPO ELISA revealed that the second peak
neither contained rhEPOfb nor protein. As the focus of this study
was on protein puriﬁcation, this peak was  not considered fur-
ther. Again, similar to ethanolamine-CNBr, low amounts of rhAEPO
seemed to bind to ethanolamine-NHS. This is also indicated by
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Fig. 4. Test of basic functionality of serotonin-NHS. Binding of recombinant human erythropoietin ﬁnal bulk (rhEPOfb) and asialo rhEPOfb (rhAEPO) to serotonin-NHS (A
and  B) and to ethanolamine-NHS (C and D) (running buffer (RB) 20 mM sodium phosphate buffer, pH 6.0). Bound rhEPOfb or rhAEPO was  eluted with 500 mM NaCl in
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Fig. 5. Dynamic binding capacities (DBC). Recombinant human erythropoietin ﬁnal
bulk rhEPOfb (dialyzed against running buffer 20 mM sodium phosphate, pH 6.0)
was  loaded onto the respective column (approx. 100 l of matrix) until the UV signal
exceeded 10% of UV maximum indicating breakthrough. Dynamic binding capacityB.  UV-absorption at 280 nm (A280) which reﬂects changes in the protein concentr
onductivity, which reﬂects the ionic strength in the buffer as red discontinuous li
otted  line ( ).
he small peak (A280,max = 16.1 mAU, VR = 21.0 ml)  during elu-
ion (Fig. 4B). Contrary to expectations, rhEPOfb was  also bound
y ethanolamine-NHS shown by the double peak (A280,max = 40.9
AU, VR = 10.1 ml;  A280,max = 61.6 mAU, VR = 12.6 m)  during elution
the second peak again did neither contain rhEPO nor protein).
his clearly suggests unspeciﬁc binding of rhEPOfb to NHS-
epharoseTM (Fig. 4C). Finally, Fig. 4D demonstrates low binding
f rhAEPO to ethanolamine-NHS. Concluding from these results
NBr seems to be preferable over NHS as matrix for serotonin
ecause of the unspeciﬁc binding of rhEPOfb to the negative control
thanolamine-NHS.
.3. Dynamic binding capacity
For all materials including WGA-agarose and the negative con-
rols of both serotonin matrices the DBC for rhEPOfb was  measured
Fig. 5). Serotonin-CNBr as well as serotonin-NHS showed the
ighest DBC, i.e. compared to WGA-agarose. Unmodiﬁed control
garose resin did not bind any rhEPOfb while ethanolamine-CNBr
ound small amounts of rhEPOfb. Furthermore, there was also
 relatively high DBC of ethanolamine-NHS indicating unspeciﬁc
inding of rhEPOfb. Although the comparison of the DBCs is difﬁcult
ue to the different characteristics of the matrices and differ-
nces in ligand density, it still could be demonstrated that the
repared serotonin materials possess a DBC higher than that of
GA-agarose. Interestingly, both serotonin materials have a com-arable DBC of about 7 mg/mlmatrix showing that the spacer did not
mprove the capacity. In contrast, the spacer of the ethanolamine-
HS matrix could even be related to the unspeciﬁc binding since it
s the only structural difference between the two  matrices.(DBC) was  calculated from the load concentration and the total load volume at 10%
breakthrough. Error bars are the SD of three runs.
3.4. Fractionation of partially puriﬁed rhEPObe
In a next step, serotonin-CNBr, serotonin-NHS and WGA-
agarose were used for fractionation of rhEPObe. Using serotonin-
CNBr and -NHS three elution steps were performed, and for
WGA-agarose only two since no further fraction could be collected.
As can be seen from Table 2, recovery of total protein and rhEPO
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s comparable for both, serotonin-CNBr (protein: 35.9% and rhEPO:
2.3%) and -NHS (protein: 47.0% and rhEPO: 65.7%) while it is much
ower for WGA-agarose (protein: 19.4% and rhEPO: 26.8%). In the
tudy of Yodoshi et al. [44] recoveries of glycopeptides of about 80%
ere achieved but elution conditions were much harsher using 30%
ethanol, which is not applicable for a preparative chromatogra-
hy of pharmaceutical purposes. The reason for low recovery in
he case of WGA-agarose might be that elution conditions were
ot optimal even though 1 M of NaCl was used for stripping. Other
esearch groups suggested the use of a competing glycan for elu-
ion like GlcNAc or sialyllactose. In particular, it was reported that
 GlcNAc concentration in the range of 15–500 mM was needed for
ull elution [45,46]. However, as addressed above, the addition of
lcNAc in the elution buffer did not result in a better separation and
s problematic regarding the subsequent glycan analysis performed
n our study (see 3.2.1). Nevertheless, for other studies, and in the
ase that no detailed glycan analysis is required, it might be useful
o include GlcNAc to improve elution and recovery of rhEPO from
GA. In general rhEPO recovery is higher than total protein recov-
ry in all cases. One reason is probably a strong unspeciﬁc binding
f some proteins to the matrix leading to a general loss of proteins.
Using the serotonin-CNBr matrix rhEPO was measured in all
f the three elution fractions but mainly in the second and third
E1: 4.1%, E2: 44.7% and E3: 13.5%). When applying serotonin-NHS,
hEPO was only detected in the ﬁrst two elution fractions (E1: 34.4%
nd E2: 31.3%) suggesting that binding of rhEPObe to this matrix
s weaker compared to serotonin-CNBr. In case of serotonin-CNBr
nd -NHS, rhEPO was only detected in the elution fractions whereas
n the case of WGA-agarose a relatively big amount was  found in
oth, the elution fractions and the stripping fraction (E1: 4.1%, E2:
4.7% and S: 13.5%), showing the strong binding of rhEPO to WGA.
The purity of rhEPO in the elution fractions of the serotonin
aterial was between 60% and 80% compared to about 39% in
he starting material rhEPObe showing that rhEPO was, besides
he fractionation, also separated from other proteins. Regarding
he serotonin materials it seems that purity decreased at high salt
oncentration. A reason might be that other proteins bound to the
olumn even stronger than rhEPO and are eluted at higher salt con-
entration. This would also explain the elution of proteins during
tripping while no rhEPO was detected in these fractions. Therefore
t would be interesting to ﬁgure out the nature of these proteins in
uture studies i.e. by the use of mass spectrometry (MS). Others
ave already shown that serotonin binds albumin [43]. an ungly-
osylated protein, as well as hydrophobic amino acids [44].
In contrast, for WGA-agarose the purity increased from 37%
n elution fraction 1–72% in elution fraction 2. In particular, the
tripping fraction seems to contain mainly rhEPO albeit in low
oncentration (5.2 g/ml). Together with the recovery results this
onﬁrms that rhEPO is bound speciﬁcally and stronger than other
roteins to WGA.
.5. Glycoanalysis
After afﬁnity chromatographic fractionation glycoanalysis of
hEPO-containing fractions was performed by xCGE-LIF to char-
cterize rhEPO N-glycosylation and to determine its degree of
ialylation. Only fractions which contained rhEPO where analyzed
see Table 2). For serotonin-CNBr, rhEPO was found in elution frac-
ions 1–3. For serotonin-NHS, rhEPO was only found in elution
raction 1 and 2. When using WGA  only two elution fractions where
btained, which both contained rhEPO. In contrast to the other
aterials, rhEPO was also found in the stripping fraction. Prioro xCGE-LIF measurements rhEPO was isolated from other pro-
eins by SDS-PAGE. The distinct band at the molecular weight of
hEPO was excised from the gel and used for further analysis. For
emi-quantitative evaluation and comparison of rhEPO glycosyla- 1012-1013 (2016) 193–203
tion of the different chromatographic fractions, RPHs from xCGE-LIF
derived N-glycan ﬁngerprints were calculated. RPHs are the ratio of
peak height to the total height of all peaks within the N-glycan ﬁn-
gerprint and correlate with the relative amounts of the respective
glycans in a sample. Based on our database (Table 1) major peaks
of the rhEPO N-glycan ﬁngerprint (Fig. 1) could be assigned to one
or more glycan structures.
Fig. 6 shows the RPHs of each glycan peak in all elution fractions
(that contained rhEPO) for every resin. For all rhEPO containing
samples, a high abundance of sialylated N-glycan structures was
found (represented by the RPHs of xCGE-LIF peaks 1–13), while the
non-sialylated N-glycan structures beyond peak 13, showed only
low abundance (not shown in the ﬁgure). Even though all analyzed
samples contained rhEPO with mainly sialylated glycan structures
and the xCGE-LIF electropherograms of the analyzed samples (data
not shown) had a similar N-glycan ﬁngerprint like pure rhEPO
(Fig. 1), it cannot be excluded completely, however, that some gly-
cans derive from proteins with a similar molecular weight as rhEPO
that were not separated by SDS-PAGE prior to xCGE-LIF. This inﬂu-
ence, if there is any, is not believed to be signiﬁcant but will be
evaluated in future experiments by MS-based proteomic analysis
of individual gel-bands.
After puriﬁcation, main changes in the RPHs can be seen for
peaks 1, 5 and 7 for all matrices. While peak 1 and 7 are assigned to
glycan structures with 3 and/or 4 sialic acids, peak 5 is assigned to
a glycan structure with only two  sialic acids. Therefore, these peaks
are indicators for an increase or decrease in the degree of sialyla-
tion. The standard deviations of peaks 5 and 7 are rather low so that
changes in RPHs shown later are believed to be signiﬁcant. In case
of peak 1, which consists of two glycan structures which are slightly
separated leading to varying peak heights, the standard deviation
is higher and differences in RPHs are not signiﬁcant but still fol-
low expected trends. It also has to be considered, that standard
deviation of the rhEPObe RPHs shown in Fig. 6 (white bars) result
from three separate measurements, meaning that materials like
SDS-PAGE gel, chemicals and enzymes were prepared separately
for each measurement. In contrast glycan analysis of the chromato-
graphic fractions was performed in one run, meaning they were all
put on one SDS-PAGE gel and treated with the same batch of pre-
pared chemicals and enzymes. Thus, it is believed that differences
in RPHs among the chromatographic fractions are more signiﬁcant
than those between the chromatographic fractions and the starting
material rhEPObe, especially for peak 1.
When using serotonin-CNBr for rhEPO fractionation, the starting
material rhEPObe was  clearly separated into 3 fractions with a dif-
ferent degree of sialylation (Fig. 6A). This can be seen, for instance,
by an increase in the RPHs of peak 1 and 7 while RPH of peak 5
is decreasing. Compared to the starting material rhEPObe (white
bars), Fig. 6A indicates for elution fraction 1 a decreased degree of
sialylation, for elution fraction 2 sialylation is similar and for elution
fraction 3 the degree of sialylation increases.
The same is more or less true for fractions obtained from
serotonin-NHS (Fig. 6B). However, rhEPO was  not found any more
in elution fraction 3 and the RPHs of elution fraction 1 and 2
seem to correspond in heights to RPHs found in elution fraction
2 and 3 of serotonin-CNBr. Elution fraction 2 of serotonin-NHS
shows even a higher degree of sialylation compared to elution
fraction 3 of serotonin-CNBr. This shows that rhEPO, with a high
degree of sialylation, elutes earlier from serotonin-NHS com-
pared to serotonin-CNBr, again indicating that rhEPO binds less
strongly to the serotonin-NHS matrix. However, also when using
serotonin-NHS, the starting material rhEPObe could be separated
into fractions of different degree of sialylation and taking into
account recoveries (Table 2), the highest amount of rhEPO with a
sialylation degree exceeding that of the starting material could be
recovered in elution fraction 2 of the serotonin-NHS afﬁnity matrix.
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Table  1
In house data base. N-Glycan structures assigned to dominant peaks of the recombinant human erythropoietin ﬁnal bulk N-glycan ﬁngerprint. Peak number refers to the
indicated peaks of the ﬁngerprint (Fig. 1). Column “N-glycan structure” shows structures, which are identiﬁed to be beyond the indicated peaks. Braces indicate that the
exact  position of the sialic acids is not known. Symbols: ( ) Fucose; ( ) N-acetylglucosamine; ( ) Mannose; ( ) Galactose; ( ) Sialic acid.
Table 2
Concentration, recovery and purity of all fractions collected from serotonin-CNBr, serotonin-NHS, and WGA-agarose. Total protein (measured by CBQCA) and recombinant
human erythropoietin (rhEPO) (measured by rhEPO speciﬁc ELISA) concentration of all fractions of the separation runs. Recovery based on loaded material (partially puriﬁed
rhEPObe); purity is the percentage ratio of rhEPO to total protein. Partially puriﬁed recombinant human erythropoietin (rhEPObe) (dialyzed against running buffer (RB)
20  mM sodium phosphate, pH 6.0) was loaded (20% of dynamic binding capacity) onto the respective column (purity of rhEPObe was 39.2 ±5.6%). Running buffer (RB) was
20  mM sodium phosphate, pH 6.0, and elution buffer (EB) was RB plus 0.3 M NaCl (0.5 M for WGA). Elution steps for serotonin-CNBr and -NHS were 10, 30 and 100% EB, and
for  WGA-agarose 25% and 100% EB.
Fractiona Protein-CBQCA rhEPO-ELISA Purity
Concentration ± SD (n = 3)
/g ml−1
Recovery ± SD (n = 3)
/%
Concentration ± SD (n = 2)
/g ml−1
Recovery ± SD (n = 2)
/%
EPO of protein ± errorb
/%
CNBr
FT 2.1 ±0.2 2.3 ±0.2 ND ND ND
E1  2.5 ±0.8 2.2 ±0.7 1.8 ±0.9 4.1 ±2.0 71.6 ±56.7
E2  25.1 ±2.7 22.5 ±2.4 19.5 ±1.6 44.7 ±3.7 77.5 ±14.5
E3  9.2 ±1.2 8.2 ±1.1 5.9 ±0.5 13.5 ±1.0 63.8 ±13.5
S  1.5 ±0.4 0.7 ±0.2 ND ND ND
Sum  35.9 ±4.6 62.3 ±6.7
NHS
FT  2.4 ±0.4 3.7 ±0.7 ND ND ND
E1  14.0 ±0.2 17.1 ±0.2 11.0 ±1.8 34.4 ±5.6 78.5 ±13.9
E2  15.5 ±2.2 19.0 ±2.7 10.0 ±1.1 31.3 ±3.6 64.3 ±16.5
E3  5.1 ±0.5 6.2 ±0.7 ND ND ND
S  1.6 ±0.3 1.0 ±0.2 ND ND ND
Sum  47.0 ±4.5 65.7 ±9.2
WGA
FT  3.2 ±1.1 4.4 ±1.5 ND ND ND
E1  4.7 ±1.2 5.3 ±1.4 1.8 c 5.0 c 37.0 ±9.6
E2  7.0 ±2.5 7.7 ±2.8 5.1 c 14.4 c 72.6 ±26.2
S  3.6 ±1.0 2.0 ±0.6 5.2 c 7.4 c 146.7 ±43.1
Sum  19.4 ±6.3 26.8 c
ND, not detected.
a Pooled fractions of each process step (FT = ﬂow through fraction; E1 = elution fraction 1; E2 = elution fraction 2; E3 = elution fraction 3; S = stripping fraction).
b Based on error propagation from SD of cprot and crhEPO.
c Not enough sample for duplicates.
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Fig. 6. Relative peak heights of partially puriﬁed recombinant human erythropoietin (rhEPObe)-containing fractions of the runs with (A) serotonin-CNBr and (B) serotonin-
NHS  and (C) WGA-agarose (Elution fraction 1 ( ); elution fraction 2 ( ); elution fraction 3 ( ); stripping fraction ( ). The white bars () refer to the starting material
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he  peak numbers refer to the peak numbers of N-glycan ﬁngerprints (see Fig. 1) an
In case of WGA-agarose (Fig. 6C) no distinct change in the RPHs
ithin the N-glycan ﬁngerprints can be seen. Only the stripping
raction shows a decrease in the RPH of peak 1 suggesting, con-
rary to expectations, that rhEPO found here was less sialylated.
GA is often described in literature as an afﬁnity ligand for N-
lycosylated proteins. On the other hand the binding of glycans
o WGA  is described as complex and is not fully understood yet.
hus it is difﬁcult to identify an optimal elution strategy. Other
tudies have shown that even the use of buffers containing up to
 M of GlcNAc only resulted in a recovery of 52% when the glyco-
rotein glycophorin was bound to WGA-Sepharose [46]. Therefore,
t is possible that rhEPO with a higher degree of sialylation can-
ot be eluted sufﬁciently from WGA-agarose. However, even in
he case that elution conditions can be further optimized, the use
f lectins for puriﬁcation of biopharmaceuticals is problematic as
t involves the risk of negative side reactions [34–36]. Therefore,
ectins should be considered only for use as a positive control
ather than ligands for downstream processing of recombinant pro-
eins.
From these results it can be concluded that both, serotonin-
NBr and -NHS, can be used for the separation of rhEPObe into
ractions containing rhEPO with different degrees of sialylation. In
omparison of the glycosylation pattern of the starting material it
eems that fractions with an increased degree of sialylation could be for missing fractions of the respective matrix or for fractions not containing rhEPO).
s to the glycan structures assigned to the peaks (see Table 1).
accumulated. With respect to the standard deviation, especially of
peak 1, that difference might however not be signiﬁcant.
For the last rhEPO elution fractions, puriﬁed by the serotonin
matrices, the glycans assigned to peak 1 and 7 of the N-glycan
ﬁngerprint make about 40% of all glycans. That is in good agree-
ment with previous studies where it has been shown that rhEPO
expressed in CHO cells contains about 40% of tetrasialylated
tetraantennary N-glycans [13,59]. It was also stated that those
glycans are the main determinant for in vivo bioactivity, while
trisialylated tetraantennary and triantennary N-glycans have no
correlation with in vivo bioactivity and the rest is negatively cor-
related [13].
Other studies have already shown that serotonin derivatized
matrices can well separate glycans with a different content of sialic
acid as well as sialylated from non-sialylated proteins [41–44].
While most of the studies focused on the separation of glycans
released from proteins [42–44] in this study the separation of
glycoforms of a single glycoprotein was  investigated. Paskhughes
[41] could separate sialylated from desialylated human chorionic
gonadotrophin by serotonin derivatized LiChrosorb Diol HPLC but
no further fractionation of sialylated protein was  achieved. To our
knowledge, this is the ﬁrst study in which glycoforms of a single
protein were separated in terms of sialic acid content by prepara-
tive afﬁnity chromatography.
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[57] J. Holgersson, A. Gustafsson, M.E. Breimer, Immunol. Cell Biol. 83 (2005) 694.
[58] M.C.M. Mellado, D. Curbelo, R. Nobrega, L.R. Castilho, J. Chem. Technol.M.  Meininger et al. / J. Chroma
. Conclusions
In this study it was  shown that the use of serotonin-coupled
atrices in downstream processing offers options for improving
he product quality of rhEPO by increasing the ratio of tetrasialy-
ated tetraantennary N-glycans in the end product. In particular, it
nables separation of low sialylated rhEPO glycoforms from highly
ialylated ones as demonstrated by xCGE-LIF analysis. Both, use
f serotonin afﬁnity chromatography to isolate rhEPO with a high
egree of sialylation and use of xCGE-LIF for at-line monitoring
ould be very useful for design and optimization of pharmaceu-
ical processes for production of rhEPO. In addition, this study can
e considered a basis for further investigations towards glycopro-
ein glycoform separation and for testing of new ligands by linking
hromatographic processes with a powerful glycoanalysis method
hat leads to an improved understanding of puriﬁcation trains.
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